Private Trust Co. NA Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Private Trust Co. NA lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 266.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 337 shares of the medical device company’s stock after buying an additional 245 shares during the period. Private Trust Co. NA’s holdings in DexCom were worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc acquired a new stake in DexCom during the fourth quarter worth $25,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth about $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth about $54,000. Rothschild Investment LLC raised its holdings in DexCom by 250.5% in the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock valued at $58,000 after buying an additional 536 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 over the last three months. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $79.51 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $84.88 and a 200-day simple moving average of $76.96. The stock has a market cap of $31.07 billion, a P/E ratio of 55.60, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DXCM shares. Citigroup boosted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Wells Fargo & Company lifted their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.